entertainment -WSS

entertainment

author：entertainment 2025-08-23 05:04:11 - browse：96

Adam's take main illustration — Molly Ferguson/STAT

Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not close. Six months from now, or sooner, Novartis will walk away — slightly embarrassed but otherwise unscathed — happy to pay a small breakup fee to MorphoSys to avoid owning a drug for myelofibrosis that regulators turned away.

MorphoSys will not fare as well from the breakup. Its future, and that of the drug called pelabresib at the center of the deal, will be thrown into limbo.

This is all speculation on my part, but it’s supported by separate conversations with two people familiar with pelabresib and the debate inside Novartis over the MorphoSys acquisition. They requested anonymity to discuss confidential matters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Chris Christie meets with Zelenskyy during Ukraine trip

WSS

Change Healthcare payments predicted restored March 15

CDC marks new Covid

With psoriasis trial ahead, Alumis raises $259 million

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

Alnylam reports growth in sales of rare disease treatments

IVF, abortion rights issues kick off Biden’s State of the Union

explore

entertainment

focus

Anesthesiologist group: stop taking Ozempic before surgery

2 officers injured in shooting in Orlando, police say

Walensky prepares to leave CDC — and Congress — behind

2 officers injured in shooting in Orlando, police say

Novavax promises a turnaround & Lilly roils the obesity market

Change Healthcare cyberattack prompts Medicare loan program

Activists slam private health insurers over coverage restrictions

A controversial new treatment promises to make little people taller

ChatGPT in medicine: STAT answers readers' burning questions

Novo Nordisk obesity pill bests Wegovy in early trial

focus

2 officers injured in shooting in Orlando, police say

Late stage cancers on the rise after pandemic delayed screenings

With psoriasis trial ahead, Alumis raises $259 million

'Null' research findings aren't empty of meaning. Let's publish them

H.R. 3 is the wrong path to lower drug costs

How I helped Pfizer think through the ethics of Viagra

hotspot

knowledge

focus

explore